盆炎康方治疗湿热瘀结型盆腔炎性疾病后遗症  

Penyankang Prescription in Treatment of Sequelae of Pelvic Inflammatory Disease with Damp-Heat Stagnation Syndrome

作　　者：刘杉杉 傅金英 徐琳琳 王艳 LIU Shanshan;FU Jinying;XU Linlin;WANG Yan(Henan University of Chinese Medicine,Zhengzhou Henan China 450046;Henan Province Hospital of Traditional Chinese Medicine/The Second Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou Henan China 450002)

机构地区：[1]河南中医药大学,河南郑州450046 [2]河南省中医院/河南中医药大学第二附属医院,河南郑州450002

出　　处：《中医学报》2023年第6期1310-1314,共5页Acta Chinese Medicine

基　　金：2022年河南省科技攻关项目-河南省教育厅(222102310459);河南中医药大学2021年教育改革研究与实践立项项目(2021JX65)。

摘　　要：目的:探析盆炎康方对湿热瘀结型盆腔炎性疾病后遗症患者的临床疗效、血清白细胞介素-2(interleukin-2,IL-2)、IL-6、IL-10、单核细胞趋化蛋白-1(monocyte chemotactic protein 1,MCP-1)及盆腔包块的影响。方法:将64例湿热瘀结型盆腔炎性疾病后遗症患者随机分成两组,对照组应用头孢唑林钠、甲硝唑治疗,治疗组在此基础上加用盆炎康方治疗,观察两组临床疗效及治疗前后中医证候积分变化情况,两组患者血清IL-2、IL-6、IL-10、MCP-1的变化情况,盆腔包块大小及中医证候积分的变化情况。结果:治疗组有效率(93.75%)明显高于对照组有效率(75.00%),差异有统计学意义(P<0.05);两组治疗后中医证候积分较治疗前均显著降低(P<0.05),且治疗组降低更明显(P<0.05);两组治疗后IL-6、MCP-1较治疗前均下降(P<0.05),且治疗组下降更明显(P<0.05);两组治疗后IL-2、IL-10较治疗前均升高(P<0.05),且治疗组升高更明显(P<0.05);两组治疗后包块较治疗前均缩小(P<0.05),且治疗组缩小更明显(P<0.05)。结论:盆炎康方可缓解湿热瘀结型盆腔炎性疾病后遗症患者的临床症状,调节血清炎性因子水平及缩小盆腔包块。Objective To explore the effect of Penyankang prescription on clinical efficacy,serum interleukin-2(IL-2),IL-6,IL-10,monocyte chemotactic protein 1(McP-1),and pelvic mass in patients with sequelae of pelvic inflammatory disease(SPID)of Damp-Heat stagnation syndrome.Methods:64 patients with sequelae of pelvic inflammatory disease of damp-heat stasis type were randomly divided into two groups.The control group was treated with cefazolin sodium and metronidazole,and the treatment group was treated with Penyankang Prescription based on that.Observe the clinical curative effect of the two groups and the changes in syndrome scores before and after treatment,the changes of serum IL-2,IL-6,IL-10,and MCP-1 in the two groups,the changes in the size of pelvic mass and the syndrome scores of the two groups.Results:The effective rate of the treatment group(93.75%)was significantly higher than that of the control group(75.00%),and the difference was statistically significant(P<0.05).The syndrome scores of the two groups after treatment were lower than those before treatment(P<0.05),and the reduction was more obvious in the treatment group(P<0.05).After treatment,IL-6 and MCP-1 in both groups decreased compared with before treatment(P<0.05),and the decrease was more obvious in the treatment group(P<0.05).After treatment,IL-2 and IL-10 in both groups increased compared with before treatment(P<0.05),and the increase was more obvious in the treatment group(P<0.05).Both groups had smaller post-treatment mass than pre-treatment(P<0.05),and the decrease was more pronounced in the treatment group(P<0.05).Conclusion:Penyankang prescription can relieve the clinical symptoms of patients with SPID of Damp-Heat stagnation syndrome by regulating the level of serum inflammatory factors and reduce pelvic mass.

关 键 词：盆腔炎性疾病后遗症 盆炎康方 湿热瘀结证 白细胞介素 盆腔包块 单核细胞趋化蛋白-1 

分 类 号：R259.113.3[医药卫生—中西医结合]